This study evaluates the effect of non-surgical periodontal therapy on salivary biomarkers (Dkk-1, Sclerostin, and PLAP-1) and clinical periodontal parameters in patients with periodontitis. Periodontitis is a chronic inflammatory disease that destroys tooth-supporting tissues. Smoking is a significant risk factor that worsens periodontal destruction and reduces the effectiveness of standard therapies. * The trial is a non-randomized comparative clinical study. * It includes 44 adult patients diagnosed with Stage II and III periodontitis. * The participants are divided into two equal groups: 22 current smokers and 22 non-smokers. * Participants will undergo a baseline examination, followed by standardized non-surgical periodontal therapy consisting of scaling and root planing. * A follow-up visit will be conducted six weeks post-therapy to repeat clinical measurements and saliva collection. * The primary objective is to evaluate changes in salivary biomarker levels and clinical parameters (Plaque Index, Gingival Index, bleeding on probing, Probing Pocket Depth, Clinical Attachment Level) after treatment.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Change in Salivary Dickkopf-1 (Dkk-1) Levels
Timeframe: Baseline and 6 weeks post-therapy.
Change in Salivary Sclerostin (SOST) Levels
Timeframe: Baseline and 6 weeks post-therapy.
Change in Salivary PLAP-1 (Asporin) Levels
Timeframe: Baseline and 6 weeks post-therapy.
Hussein Abdul-Rassul Hatiem, B.D.S., M.Sc. Student